Key Insights

Highlights

Treatment Research

1 treatments under study, led by Lenshooke X12 Device

Research Leaders

5 sponsors active, led by Organon

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

50.0%

1 terminated out of 2 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

0

Data Visualizations

Phase Distribution

Trial Status

Not Yet Recruiting1
Terminated1

Clinical Trials (2)

Showing 2 of 2 trials
NCT07621991Not Yet Recruiting

Clinical Thresholds of Double-strand Breaks in Sperm's DNA in ART

NCT00875095TerminatedPrimary

Impact of Sperm DNA Integrity on Artificial Reproductive Treatment (ART)

Showing all 2 trials

Research Network

Common Treatments

  • Lenshooke X12 Device1

Active Sponsors

  • Organon1
  • Indira IVF Hospital Pvt Ltd1
  • Bonraybio Co. Ltd.1
  • ADVY Chemical Private Limited1
  • Northwell Health1

Top Investigators

Related Conditions

  • Sperm Dna Fragmentation1

Activity Timeline